Metoprolol Formulation Selection for Hypertension and Heart Failure

Introduction to Formulation Differences

The American College of Cardiology recommends metoprolol succinate for chronic hypertension management due to its sustained 24-hour beta-blockade with once-daily dosing, which is superior to the faster but shorter-acting tartrate formulation 1, 2

Both metoprolol tartrate and succinate are acceptable for hypertension according to ACC/AHA guidelines, with metoprolol tartrate at 25-100 mg twice daily being equivalent to metoprolol succinate 50-200 mg once daily 2
For patients with both hypertension and heart failure, metoprolol succinate is mandatory, as it has demonstrated mortality benefits, whereas the tartrate formulation lacks proven mortality benefits and performed worse than carvedilol in direct comparison trials 3, 4

Metoprolol succinate is preferred over tartrate for heart failure patients, as it reduced mortality by 34% in the MERIT-HF trial, and the COMET trial showed that metoprolol tartrate was inferior to carvedilol 3, 4
The European Society of Cardiology recommends starting metoprolol succinate at 12.5-25 mg once daily and titrating to a target dose of 200 mg once daily for patients with heart failure and reduced ejection fraction 2, 4

For hypertension alone, either formulation is acceptable, but metoprolol succinate is preferred for once-daily convenience and consistent 24-hour coverage 1, 2
For hypertension with stable ischemic heart disease, either formulation is acceptable for blood pressure control, and both provide antianginal benefits 1